Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dosing begins in phase I trial of antisense therapy ATL-1103

June 30, 2011

Living Cell Technologies begins enrollment in phase II Diabecell trial

June 30, 2011

CNX-011-67 improves responsiveness to glucose in models of diabetes

June 30, 2011

Phase III trial evaluates linagliptin/metformin combination in type 2 diabetes

June 30, 2011

PSN-821 reduces energy intake in patients with obesity and type 2 diabetes

June 29, 2011

SK Chemicals' new 11-beta-HSD1 inhibitor SKI-2852 is active in models of diabetes

June 29, 2011

Novel AMPK activators synthesized

June 29, 2011

New beta-secretase 2 inhibitors for diabetes patented by Roche

June 29, 2011

FDA grants fast track status to SBC-102 in lysosomal acid lipase deficiency

June 28, 2011

FDA accepts Prochieve progesterone gel NDA for filing

June 28, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...